Introduction
In 1976 Mato et al of Japan reported "flourescent material" in the blood of schizophrenics. This material was seen in the platelets and the leucocytes. A similar report appeared out of Russia in 1976 by Averkin et al. The Russian report claimed "activated lymphocytes". Biopsy material was used.
Bonartsev (1976)
This was a banner year for schizophrenia research. Bonartsev, a brilliant Russian scientist, also reported activated lymphocytes in schizophrenia. Bonartsev called them "atypical". They were more adhesive and had wider cytoplasms.
Bonartsev & Buravlev (1977)
In this study lymphocytes were incubated with brain cells. The activated lymphocytes from schizophrenics "called forth degenerative changes in the cells of brain culture in the area of contacts". "The lymphocytes of the patients are characterized by an increased amount of cytoplasmic processes."
Solov'eva & Orlovskaia (1977)
These Russian scientists found lipofuscin in "cells of the embryonic brain". This study was on abortions from schizophrenic Mothers. This suggests a toxic factor in the blood of the Mothers. The lipofuscin could be a residue of the toxin. This apears consistent with the Japanese report because dopamine is flourescent. The lipofuscin could come from a dopamine metabolite.
Scientific Biography: Dide
Maurice Dide was a psychiatrist who was born in 1873 and died in 1944. Dide was born in Paris. Dide studied schizophrenia, which was then called "dementia praecox". He reported anatomic and histologic lesions in the basal ganglia and the thalamus of schizophrenics. He published a paper on this in 1921. Recent MRI studies have confirmed the work of Dide. If this work is correct, this appears to suggest the possible involvement of dopamine, which is found in high concentrations in the basal ganglia and the thalamus.
Functional Studies in Schizophrenia
In 1992 Tamminga et al reported a PET study with FDG, an analog of glucose. This study showed reduced glucose metabolism in schizophrenia in the parahippocampal gyrus. Dr. Carol Tamminga worked on a chapter of a book published in 2002 called "Textbook of Neuropsychiatry and Clinical Neurosciences". The book was edited by Yudofsky and Hales.
Lafayette Clinic Work Confirmed
The work of Tamminga et al partly confirms previous work by the Lafayette Clinic in Detroit. In 1971 a book was published entitled "The World Biennial of Psychiatry and Psychotherapy", edited by Sivano Arieti. Volume I included a chapter by Beckett and Gottlieb. These Detroit workers reported "a plasma factor or factors" that was (were) toxic. One protein was called "factor 1". A Russian group confirmed "factor 1". It was a high molecular weight alpha globulin that was labile. This factor was also confirmed using a different assay by Bergen and his group in Massachusetts. The factor caused a disturbance in carbohydrate metabolism. Frohman reported that the factor caused hemolysis (destruction of erythrocytes). The Detroit group found that the problem was caused by an increased cellular uptake of amino acids, including tryptophan.
Giants of Science: Dr. Alexander Shulgin
Much of my research on Shulgin has been done on the internet, which contains massive amounts of information about this drug guru. Shulgin is a professor at University of California in Berkeley. California is no stranger to controversy after housing Linus Pauling at Cal Tech and later at Stanford. However, Shulgin has a completely different approach than Pauling. Pauling was an anti-war activist, which alienated him from the government, although he was very popular throughout the world.
Drugs
Although Linus Pauling was critical of drugs, including cold medicines, Shulgin favors drugs. Shulgin is considered a leading expert on drugs of abuse. Shulgin has also studied DMPEA, a very controversial substance found only in schizophrenics and in the peyote cactus. There has been much controversy as to whether DMPEA is psychoactive. It has been proven to be psychoactive in animals, but Shulgin disputes its effect on humans, if any. One problem is that certain substances are weak when given by mouth because of the fact that the digestive system can destroy them. This is seen in the case of insulin. Another problem is that the blood-brain barrier excludes certain substances, making the therapy of Parkinson's disease difficult. Thus dopamine is not given to Parkinsonian patients, but large doses of L-dopa are used instead. Shulgin, who is called "Sasha" as a nickname, is over 70 years old. He began publishing articles in 1961 and is still going strong. He took an interest in schizophrenia for a while, but is now mostly interested in psychedelic drugs, which can simulate schizophrenia.
Conclusions
Bonartsev (1977) felt that "the blood of schizophrenic patients contains biologically active substances, which bring on an increase of adhesive properties in the lymphocytes and their physiological activation." These cells had wide cytoplasms. The "fluorescent substance" reported by the Japanese group may be the toxin. This toxin causes the "acute swelling" of neurons seen in schizophrenia by Orlovskaia et al.
But what do you do about it? The answer may be a diet very low in amino acids. It may be that amino acids are flooding the cells and causing them to blow up like balloons and burst. This is also causing the slowing of glucose metabolism because the brain is burning amino acids instead of glucose. Thus we have a diabetes of the brain.
There are many false theories. Psychoanalysis has failed. One psychoanalyst, Reich, was even put in jail for pretending to have a cure for cancer. Scientology is a quack attack. Quackery pretends to be science. Psychoanalysts have built castles in the air, according to Kraepelin of Germany. They leap over scientific barriers. People have spend enormous amounts of money on psychoanalysis and have gotten nothing for it.
Reference
1. Sargent, T. W., D. M. Israelstrom, A. T. Shulgin, S. A. Landaw, and N. N. Finley, "A note concerning the fate of the 4-methoxy group in 3,4-dimethoxyphenethylamine (DMPEA)", Biochem. Biophys. Res. Commun. 29: 126-130.


Comments: 6
The effect of plasma from psychotic children on tryptophan uptake in chicken erythrocytes.Piggott LR, Forhman CE, Ward VL, Gottlieb JS.
Ten children diagnosed as psychotic by the DeMeyer-Churchill guidelines were matched for age and sex with ten non-psychotic but emotionally disturbed children. Six of the ten pairs were medication free. In four of the ten pairs, at least one member was medicated at the time of testing. The plasma of the children diagnosed as psychotic caused a significantly (p less than 0.025) greater uptake of tryptophan by chicken red blood cells than did the serum of their control group. This is the same effect on tryptophan uptake as found when the plasma of adult patients with process schizophrenia is incubated with chicken erythrocytes and tryptophan. This finding lends support to the possibility that there is a subgroup of childhood psychotic patients who have a biological disturbance similar to that found in adult process schizophrenia patients.
Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder.
Miller CL, Llenos IC, Cwik M, Walkup J, Weis S.
Stanley Division for Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 1105, Baltimore, MD 21287, USA.
Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder. To identify components of the pathway that may be relevant as biomarkers or may underlie the etiology of psychosis, it is essential to characterize the extent of kynurenine pathway activation and to investigate known regulators of one of the key kynurenine-producing enzymes, tryptophan 2,3-dioxygenase (TDO2), previously shown in this laboratory to be increased commensurate with kynurenine in postmortem anterior cingulate brain tissue from individuals with schizophrenia. Using this same anterior cingulate sample set from individuals with schizophrenia, bipolar disorder, depression and controls (N=12-14 per group), we measured the precursor of kynurenine and two downstream products. The precursor, tryptophan, was significantly increased only in the schizophrenia group (1.54-fold the mean control value, p=0.02), and through substrate-induced activation, may be one cause of the increased kynurenine and kynurenine metabolites. This finding for tryptophan differs from some, but not all, previous reports and methodological reasons for the discrepancies are discussed. A product of kynurenine metabolism, 3-OH-anthranilic acid was also significantly increased only in the schizophrenia group (1.68-fold the mean control value, p=0.03). 3-OH-anthranilic acid is a reactive species with cytotoxic properties, although the threshold for such effects is not known for neurons. Analysis of major pre- and post-mortem variables showed that none were confounding for these between-group experimental comparisons. Nicotinamide, a pathway end product, did not differ between groups but was associated with cause of death (suicide) within the bipolar group (p=0.03).
PMID: 18328600 [PubMed - as supplied by publisher]
Brain Res. 2006 Feb 16;1073-1074:25-37. Epub 2006 Jan 30. Links
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.Miller CL, Llenos IC, Dulay JR, Weis S.
Stanley Division of Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University, 600 N. Wolfe St./Blalock 1105, Baltimore, MD 21287, USA. Cmiller2@jhmi.edu
Upregulation of the kynurenine pathway has been associated with several etiologies of psychosis, an indication that increased levels of pathway intermediates might be involved in eliciting some psychotic features. In schizophrenia, tryptophan 2,3-dioxygenase (TDO2) was previously identified in postmortem frontal cortex as the enzyme likely responsible for the reported increase in pathway activity in the brain. For this follow-up study of postmortem anterior cingulate gyrus, we have found evidence of increased TDO2 activity in schizophrenia at three different levels of regulation: mRNA, protein, and metabolic product. The results were unaffected by neuroleptic status or smoking history. To make the distinction between mental disorders with psychosis and those without, this study included patients with bipolar disorder and major depression. Compared to the control group, the HPLC, RT-PCR, and immunohistochemistry results show significant elevation of (1) kynurenine in schizophrenia (1.9-fold, P = 0.02), and in bipolar disorder (1.8-fold, P = 0.04), primarily in the bipolar subgroup with psychosis (2.1-fold, P = 0.03); (2) TDO2 mRNA in schizophrenia (1.7-fold; P = 0.049); and (3) the immunohistochemistry values for the density of TDO2-positive white matter glial cells in schizophrenia (P = 0.01) and in major depression (P = 0.03) as well as the density and intensity of glial cells (in both gray and white matter) stained for TDO2 in bipolar disorder (P = 0.02). Unlike the results for schizophrenia and bipolar disorder, the increase in TDO2 protein in the major depression group was not associated with an increase in kynurenine concentration.